文献速递肿瘤 PET/CT

18F-DCFPyL PET/CT对根治后生化复发激素敏感前列腺癌治疗决策的影响:多中心回顾性研究

Management impact of 18F-DCFPyL PET/CT in hormone-sensitive prostate cancer patients with biochemical recurrence after definitive treatment: a multicenter retrospective study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-02-05

该多中心回顾性研究纳入253例根治性治疗后生化复发(BCR)的激素敏感前列腺癌患者,评估18F-DCFPyL PET/CT再分期对治疗决策的影响。两位泌尿肿瘤专科医生分别在知晓PET/CT结果前后制定首选治疗方案,结果显示40.7%(103/253)的病例治疗意图发生改变。在根治性前列腺切除术后患者中,PET/CT阳性、病理淋巴结阳性(pN1)与治疗改变呈正相关,而手术切缘阳性呈负相关。

要点

  • 18F-DCFPyL PET/CT使40.7%的生化复发激素敏感前列腺癌患者治疗决策发生改变。
  • 根治术后患者中,PET/CT阳性和pN1是治疗改变的显著预测因素。
  • 手术切缘阳性与治疗改变呈独立负相关(OR 0.42)。

核心结论

  • 18F-DCFPyL PET/CT对生化复发激素敏感前列腺癌患者的拟定治疗管理具有显著影响。
  • PET/CT阳性、病理淋巴结阳性(pN1)与治疗改变几率增加显著相关,手术切缘阳性与治疗改变几率降低显著相关。

研究设计与样本

  • 多中心回顾性研究,共纳入253例根治性治疗后生化复发(BCR)的激素敏感前列腺癌患者,均接受18F-DCFPyL PET/CT再分期。
  • 由两位泌尿肿瘤专科医生分别在知晓PET/CT结果前后为每例患者制定首选治疗方案。

主要发现

  • 253例中191例(75%)以机器人辅助根治性前列腺切除术(RARP)为初始治疗,62例(25%)接受外照射放疗(EBRT)。
  • 103/253例(40.7%)基于18F-DCFPyL PET/CT结果报告了首选治疗改变。
  • RARP术后患者中,PET/CT阳性(OR 6.21;95%CI 2.78-13.8;p < 0.001)和病理淋巴结阳性pN1(OR 2.96;95%CI 1.15-7.60;p = 0.024)是治疗意图改变的显著预测因素。
  • 手术切缘阳性与治疗意图改变呈负相关(OR 0.42;95%CI 0.20-0.88;p = 0.022)。

临床怎么用

  • 对根治性治疗后生化复发的激素敏感前列腺癌患者,18F-DCFPyL PET/CT再分期可提供影响治疗决策的信息。
  • 根治术后患者若PET/CT阳性或病理淋巴结阳性,应预期治疗决策可能因PET/CT结果而调整。

局限性

  • 本研究为回顾性设计,治疗改变为医生拟定的首选方案而非实际实施的治疗。
  • 研究仅纳入激素敏感生化复发患者,结论不宜外推至其他疾病阶段。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to investigate whether an early, accurate identification of disease using 18F-DCFPyL PET/CT imaging resulted in a change of decision on treatment management, for individual patients with biochemically recurrent (BCR), hormone-sensitive prostate cancer. METHODS: In this retrospective study, a total of 253 patients with BCR who underwent restaging 18F-DCFPyL PET/CT were assessed. Two urologists specialized in uro-oncology were asked to formulate a preferred treatment for each patient before and after knowing the results of the 18F-DCFPyL PET/CT. RESULTS: Out of 253 patients, 191 (75%) underwent robot-assisted radical prostatectomy (RARP) as primary therapy, and 62 (25%) external beam radiation therapy (EBRT). In 103/253 cases (40.7%), a preferred treatment change based on the 18F-DCFPyL PET/CT findings was reported. In patients post-RARP, a positive 18F-DCFPyL PET/CT (OR 6.21; 95%CI 2.78-13.8; p < 0.001) and positive pathological lymph node status (pN1) (OR 2.96; 95%CI 1.15-7.60; p = 0.024) were significant predictors for an intended change of management, whereas a positive surgical margin (OR 0.42; 95%CI 0.20-0.88; p = 0.022) was inversely associated with an intended change of management. CONCLUSION: In this study, we found a significant impact of 18F-DCFPyL PET/CT on the intended management of patients with biochemically recurrent hormone-sensitive prostate cancer. A positive 18F-DCFPyL PET/CT scan, positive pathological lymph node status, and a negative surgical margin status were significantly associated with increased odds of having a change of management based on 18F-DCFPyL PET/CT findings.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Meijer D, van Leeuwen PJ, Oosterholt PMJ, et al. Management impact of 18F-DCFPyL PET/CT in hormone-sensitive prostate cancer patients with biochemical recurrence after definitive treatment: a multicenter retrospective study. Eur J Nucl Med Mol Imaging. 2021. PMID: 33547552. doi:10.1007/s00259-021-05222-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。